191 related articles for article (PubMed ID: 11761229)
1. MuLV packaging systems as models for estimating/measuring retrovirus recombination frequency.
Patience C; Takeuch Y; Cosset FL; Weiss RA
Dev Biol (Basel); 2001; 106():169-79; discussion 253-63. PubMed ID: 11761229
[TBL] [Abstract][Full Text] [Related]
2. Packaging of endogenous retroviral sequences in retroviral vectors produced by murine and human packaging cells.
Patience C; Takeuchi Y; Cosset FL; Weiss RA
J Virol; 1998 Apr; 72(4):2671-6. PubMed ID: 9525584
[TBL] [Abstract][Full Text] [Related]
3. The potential of retroviral vectors to cotransfer human endogenous retroviruses (HERVs) from human packaging cell lines.
Zeilfelder U; Frank O; Sparacio S; Schön U; Bosch V; Seifarth W; Leib-Mösch C
Gene; 2007 Apr; 390(1-2):175-9. PubMed ID: 17045761
[TBL] [Abstract][Full Text] [Related]
4. Suspension packaging cell lines for the simplified generation of T-cell receptor encoding retrovirus vector particles.
Reuss S; Biese P; Cosset FL; Takeuchi Y; Uckert W
Gene Ther; 2007 Apr; 14(7):595-603. PubMed ID: 17235289
[TBL] [Abstract][Full Text] [Related]
5. Generation of stable retrovirus packaging cell lines after transduction with herpes simplex virus hybrid amplicon vectors.
Sena-Esteves M; Hampl JA; Camp SM; Breakefield XO
J Gene Med; 2002; 4(3):229-39. PubMed ID: 12112640
[TBL] [Abstract][Full Text] [Related]
6. Specific packaging of spliced retroviral vector transcripts lacking the Psi-region.
Pambalk K; Hohenadl C; Salmons B; Günzburg WH; Renner M
Biochem Biophys Res Commun; 2002 Apr; 293(1):239-46. PubMed ID: 12054590
[TBL] [Abstract][Full Text] [Related]
7. Characterization of human endogenous retrovirus type K virus-like particles generated from recombinant baculoviruses.
Tönjes RR; Boller K; Limbach C; Lugert R; Kurth R
Virology; 1997 Jul; 233(2):280-91. PubMed ID: 9217052
[TBL] [Abstract][Full Text] [Related]
8. Development of a suspension packaging cell line for production of high titre, serum-resistant murine leukemia virus vectors.
Pizzato M; Merten OW; Blair ED; Takeuchi Y
Gene Ther; 2001 May; 8(10):737-45. PubMed ID: 11420637
[TBL] [Abstract][Full Text] [Related]
9. Packaging of heterologous RNAs by a minimal bovine leukemia virus RNA packaging signal into virus particles.
Jewell NA; Mansky LM
Arch Virol; 2005 Jun; 150(6):1161-73. PubMed ID: 15703852
[TBL] [Abstract][Full Text] [Related]
10. Targeted gene transfer to lymphocytes using murine leukaemia virus vectors pseudotyped with spleen necrosis virus envelope proteins.
Engelstädter M; Buchholz CJ; Bobkova M; Steidl S; Merget-Millitzer H; Willemsen RA; Stitz J; Cichutek K
Gene Ther; 2001 Aug; 8(15):1202-6. PubMed ID: 11509952
[TBL] [Abstract][Full Text] [Related]
11. Intracellular trafficking of Gag and Env proteins and their interactions modulate pseudotyping of retroviruses.
Sandrin V; Muriaux D; Darlix JL; Cosset FL
J Virol; 2004 Jul; 78(13):7153-64. PubMed ID: 15194792
[TBL] [Abstract][Full Text] [Related]
12. A packaging cell line generating CD4-specific retroviral vectors for efficient gene transfer into primary human T-helper lymphocytes.
Thaler S; Schnierle BS
Mol Ther; 2001 Sep; 4(3):273-9. PubMed ID: 11545619
[TBL] [Abstract][Full Text] [Related]
13. Characterization of an alternative packaging system derived from the cat RD114 retrovirus for gene delivery.
Ghani K; Cottin S; de Campos-Lima PO; Caron MC; Caruso M
J Gene Med; 2009 Aug; 11(8):664-9. PubMed ID: 19507185
[TBL] [Abstract][Full Text] [Related]
14. Transmission of endogenous VL30 retrotransposons by helper cells used in gene therapy.
Chakraborty AK; Zink MA; Hodgson CP
Cancer Gene Ther; 1994 Jun; 1(2):113-8. PubMed ID: 7621242
[TBL] [Abstract][Full Text] [Related]
15. A murine leukemia virus derived retroviral vector with a rat VL30 packaging psi sequence.
Torrent C; Wang P; Darlix JL
Bone Marrow Transplant; 1992; 9 Suppl 1():143-7. PubMed ID: 1324044
[TBL] [Abstract][Full Text] [Related]
16. Protection of MLV vector particles from human complement.
Breun S; Salmons B; Günzburg WH; Baumann JG
Biochem Biophys Res Commun; 1999 Oct; 264(1):1-5. PubMed ID: 10527830
[TBL] [Abstract][Full Text] [Related]
17. Evidence for nonspecific adsorption of targeted retrovirus vector particles to cells.
Pizzato M; Blair ED; Fling M; Kopf J; Tomassetti A; Weiss RA; Takeuchi Y
Gene Ther; 2001 Jul; 8(14):1088-96. PubMed ID: 11526456
[TBL] [Abstract][Full Text] [Related]
18. A retroviral packaging cell line for pseudotype vectors based on glioma-infiltrating progenitor cells.
Fischer YH; Miletic H; Giroglou T; Litwak S; Stenzel W; Neumann H; von Laer D
J Gene Med; 2007 May; 9(5):335-44. PubMed ID: 17474071
[TBL] [Abstract][Full Text] [Related]
19. High efficiency retroviral vectors that contain no viral coding sequences.
Yu SS; Kim JM; Kim S
Gene Ther; 2000 May; 7(9):797-804. PubMed ID: 10822307
[TBL] [Abstract][Full Text] [Related]
20. The envelope glycoprotein of human endogenous retrovirus HERV-W induces cellular resistance to spleen necrosis virus.
Ponferrada VG; Mauck BS; Wooley DP
Arch Virol; 2003 Apr; 148(4):659-75. PubMed ID: 12664292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
